Google
×
Showing results for Prometheus Biosciences
Search instead for PrometheusBiosciences
Jun 16, 2023 · Under the terms of the acquisition agreement, Merck, through a subsidiary, has acquired all outstanding shares of Prometheus for $200.00 per ...
People also ask
We are a specialty clinical laboratory enabling precision-guided care in Inflammatory Bowel Disease and other GI disorders. We discover, develop and ...
Apr 17, 2023 · Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, picking up a promising experimental treatment for ...
Apr 16, 2023 · Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...
Jan 8, 2023 · Prometheus Biosciences, Inc. (Nasdaq: RXDX), is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.
Jun 19, 2023 · Merck finalized its acquisition of immune-focused Prometheus Biosciences for approximately $10.8 billion, scoring five clinical and pre-clinical ...
Prometheus Biosciences is a biotechnology company specializing in developing precision therapies for immune-mediated diseases using a one-of-a-kind ...
Apr 17, 2023 · Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, the companies said Sunday.
Mar 7, 2024 · We empower healthcare specialists with the ability to accelerate the achievement of sustained disease remission and disease control.
Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.